Pancreatic Cancer Research

ResearcherChiba UniversityActive in the last 2 years

Hideyuki Yoshitomi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2911-8056; OpenAlex author ID A5020490910. Sources: OpenAlex.

Their work

Papers
36 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
70
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 3 papers · 2016: 4 papers · 2017: 7 papers · 2018: 3 papers · 2019: 4 papers · 2020: 5 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 36

  1. Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP0… Co-author DOI 10.1097/sla.0000000000006730↗
  2. Investigation of CRP and NLR as potential biomarkers for redefining biological borderline resectable pancreatic cancer. Last author DOI 10.3892/ol.2026.15783↗
  3. Needle tract seeding after fine-needle aspiration for pancreatic cancer assessed by endoscopy and endoscopic ultrasound. Co-author DOI 10.1055/a-2738-7245↗
  4. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma w… Co-author DOI 10.1186/s13063-022-06049-7↗
  5. Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer. Co-author DOI 10.1007/s13402-021-00614-z↗
  6. [Ⅲ.Surgical Treatment for Recurrence of Pancreatic Cancer]. Co-author PMID 34657053↗
  7. Comparing prognostic factors of Glut-1 expression and maximum standardized uptake value by FDG-PET in patients with resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.07.407↗
  8. Diverse transitions in diabetes status during the clinical course of patients with resectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyaa136↗
  9. Endoscopic Ultrasound Criteria for Arterial Invasion in Pancreatic Cancer of the Body and Tail. Co-author DOI 10.1097/mpa.0000000000001523↗
  10. Needle tract seeding recurrence of pancreatic cancer in the gastric wall with paragastric lymph node metastasis after endoscopic ultrasound-guided fine needle … Co-author DOI 10.1186/s12876-020-1159-x↗
  11. [Ⅱ.Carbon Ion Radiation Therapy as Perioperative Treatment for Pancreatic Cancer]. Co-author PMID 33130735↗
  12. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Co-author DOI 10.1007/s00595-019-01804-x↗
  13. Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer? Co-author DOI 10.1186/s12957-019-1667-8↗
  14. Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plu… Co-author DOI 10.3892/mco.2019.1807↗
  15. [Postoperative Recurrence of Pancreatic Cancer Successfully Treated with the Gemcitabine plus Oxaliplatin Regimen Resulting in Long-Term Survival-ACase Report]. Co-author PMID 30765668↗
  16. Expression of annexin II and stromal tenascin C promotes epithelial to mesenchymal transition and correlates with distant metastasis in pancreatic cancer. Co-author DOI 10.3892/ijmm.2018.3652↗
  17. Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report. Co-author DOI 10.3892/mco.2018.1688↗
  18. [Pancreas Bed Recurrence Resection Combined with Celiac and Common Hepatic Arterial Resection after Distal Pancreatectomy for Pancreatic Cancer]. First author PMID 29362327↗
  19. Grainyhead-like 2 (GRHL2) regulates epithelial plasticity in pancreatic cancer progression. Co-author DOI 10.1002/cam4.1212↗
  20. Combined hepatic arterial resection in pancreatic resections for locally advanced pancreatic cancer. First author DOI 10.1007/s00423-017-1578-5↗
  21. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal ad… Co-author DOI 10.1016/j.cyto.2017.02.007↗
  22. Sex Determining Region Y Box 9 Induces Chemoresistance in Pancreatic Cancer Cells by Induction of Putative Cancer Stem Cell Characteristics and Its High Expres… First author DOI 10.1097/mpa.0000000000000945↗
  23. Immune-complex level of cofilin-1 in sera is associated with cancer progression and poor prognosis in pancreatic cancer. Co-author DOI 10.1111/cas.13181↗
  24. Metadherin promotes metastasis by supporting putative cancer stem cell properties and epithelial plasticity in pancreatic cancer. Co-author DOI 10.18632/oncotarget.19802↗
  25. [IV. Distal Pancreatectomy with Celiac Axis Resection(DP-CAR)for Locally Advanced Pancreatic Cancer with Celiac Artery Invasion]. Co-author PMID 29066679↗
  26. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags. Co-author DOI 10.1038/bjc.2016.295↗
  27. Low Stromal Area and High Stromal Microvessel Density Predict Poor Prognosis in Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000000499↗
  28. [Two Cases of Remnant Pancreatic Cancer Treated Using Remnant Pancreatectomy Combined with Hepatic Arterial Resection]. Co-author PMID 28133092↗
  29. [A Case of Early-Onset Rapidly Progressive Cerebral Infarction with Trousseau's Syndrome in a Patient with Pancreatic Cancer Undergoing Surgery]. Co-author PMID 28133197↗
  30. Prognostic relevance of apparent diffusion coefficient obtained by diffusion-weighted MRI in pancreatic cancer. Co-author DOI 10.1002/jmri.24939↗
  31. [III. Repeat pancreatectomy for recurrent pancreatic cancer]. Co-author PMID 26665417↗
  32. [A Case of R0 Resection of Locally Advanced Pancreatic Cancer Following Chemoradiation Therapy]. Co-author PMID 26805371↗
  33. Tips and tricks of surgical technique for pancreatic cancer: portal vein resection and reconstruction (with videos). Co-author DOI 10.1002/jhbp.128↗
  34. [Liver, pancreas, biliary tract cancer. III. Pancreatectomy with Vascular Resection for Locally Advanced Pancreatic Cancer]. Co-author PMID 25528776↗
  35. Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. Co-author DOI 10.1016/j.jss.2012.05.065↗
  36. The application of a three-step proteome analysis for identification of new biomarkers of pancreatic cancer. Co-author DOI 10.1155/2011/628787↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Ohtsuka · 26 shared papers, 2012–2021 · strength 1.92
  2. Shigetsugu Takano · 27 shared papers, 2011–2021 · strength 1.91
  3. Masaru Miyazaki · 26 shared papers, 2011–2021 · strength 1.70
  4. Katsunori Furukawa · 22 shared papers, 2012–2021 · strength 1.49
  5. Shingo Kagawa · 19 shared papers, 2012–2021 · strength 1.24
  6. Hidehiro Tajima · 2 shared papers, 2025–2026 · strength 0.62
  7. Rintaro Mikata · 5 shared papers, 2015–2020 · strength 0.39
  8. Sohei Satoi · 2 shared papers, 2022–2026 · strength 0.37
  9. Hideki Ueno · 2 shared papers, 2022–2026 · strength 0.37
  10. Michiaki Unno · 2 shared papers, 2022–2026 · strength 0.37
  11. Tsutomu Fujii · 2 shared papers, 2022–2026 · strength 0.37
  12. Fuyuhiko Motoi · 2 shared papers, 2022–2026 · strength 0.37
  13. Keishi Kawasaki · 1 shared paper, 2026 · strength 0.33
  14. Masaya Tamano · 1 shared paper, 2025 · strength 0.28
  15. Koichi Soga · 1 shared paper, 2025 · strength 0.28
  16. Mamoru Satoh · 5 shared papers, 2011–2021 · strength 0.27
  17. Fumio Nomura · 5 shared papers, 2011–2021 · strength 0.27
  18. Tetsuo Yokota · 3 shared papers, 2018–2020 · strength 0.26
  19. Reiri Shimazaki · 3 shared papers, 2017–2021 · strength 0.25
  20. Tomoo Kosuge · 1 shared paper, 2026 · strength 0.25
  21. Keita Wada · 1 shared paper, 2026 · strength 0.25
  22. Shinichiro Takahashi · 1 shared paper, 2026 · strength 0.25
  23. Masayuki Sho · 1 shared paper, 2026 · strength 0.25
  24. Hirochika Toyama · 1 shared paper, 2026 · strength 0.25
  25. Ippei Matsumoto · 1 shared paper, 2026 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.